1,145
Views
43
CrossRef citations to date
0
Altmetric
Review

The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders?

, &
 

Abstract

Brexpiprazole is a serotonin–dopamine activity modulator in clinical development for schizophrenia, adjunctive treatment of major depressive disorder, agitation in Alzheimer’s disease and post-traumatic stress disorder. It is a partial agonist at 5-HT1A and D2 receptors with similar potency, and an antagonist at 5-HT2A and adrenergic α1B/2C receptors. Compared with aripiprazole, brexpiprazole is more potent at 5-HT1A receptors and displays less intrinsic activity at D2 receptors. This unique serotonin and dopamine modulatory activity has shown robust antipsychotic, antidepressant-like and anxiolytic activities, and limited extrapyramidal symptom liability with pro-cognitive efficacy in animal models. Phase III clinical trials have been successfully completed in schizophrenia and adjunctive use in major depressive disorder, with the US FDA approval obtained for these uses; Phase III studies in Alzheimer’s disease and post-traumatic stress disorder are ongoing.

Acknowledgements

In the past 36 months, L Citrome has been engaged in collaborative research with, or received consulting or speaking fees, from: Alexza, Alkermes, Allergan (Actavis, Forest), AstraZeneca, Avanir, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Forum, Genentech, Janssen, Jazz, Lundbeck, Merck, Medivation, Mylan, Novartis, Noven, Otsuka, Pfizer, Reckitt Benckiser, Reviva, Shire, Sunovion, Takeda, Teva and Valeant. K Maeda is a full-time employee of Otsuka Pharmaceutical Co., Ltd, Tokyo, Japan. TB Stensbøl is a full-time employee of H. Lundbeck A/S. Mark Hughes, PhD, (QXV Communications, an Ashfield business, part of UDG Healthcare Plc, Macclesfield, UK) provided medical writing assistance, which was funded by Otsuka Pharmaceutical Development & Commercialization, Inc. (Princeton, USA) and H. Lundbeck A/S (Valby, Denmark).

Financial & competing interests disclosure

L Citrome has served as a consultant for Alexza, Alkermes, Allergan (Actavis, Forest), Avanir, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Forum, Genentech, Janssen, Jazz, Lundbeck, Merck, Medivation, Mylan, Novartis, Noven, Otsuka, Pfizer, Reckitt Benckiser, Reviva, Shire, Sunovion, Takeda, Teva and Valeant. L Citrome has served as a speaker for Allergan (Actavis, Forest), AstraZeneca, Janssen, Jazz, Lundbeck, Merck, Novartis, Otsuka, Pfizer, Shire, Sunovion, Takeda and Teva. L Citrome also has stocks in Bristol-Myers Squibb, Eli Lilly, J & J, Merck and Pfizer. TB Stensbøl is a full-time employee of H Lundbeck. K Maeda is a full-time employee of Otsuka Pharmaceuticals, Japan. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Key issues
  • Brexpiprazole is a serotonin–dopamine activity modulator.

  • Brexpiprazole has high binding affinities for 5-HT1A and D2 receptors, where it acts as a partial agonist. Compared with aripiprazole, it is more potent at 5-HT1A receptors and displays less intrinsic activity at D2 receptors. Brexpiprazole also has antagonistic activity at several 5-HT receptors including 5-HT2A, as well as at α1B/2C-adrenergic receptors.

  • At clinically relevant doses that showed good D2 receptor occupancies in vivo, brexpiprazole demonstrated robust effects in animal models predictive of antipsychotic effects in schizophrenia.

  • Brexpiprazole demonstrated pro-cognitive effects in rodents, including the reversal of phencyclidine-induced cognitive impairment in executive function.

  • Adjunctive brexpiprazole demonstrated effects in animal models of depression- and anxiety-like behavior, including effects in mice on measures of immobility time in the forced swim test and on the reduction in marble-burying behavior.

  • Brexpiprazole demonstrated nerve growth factor–induced neurite outgrowth, suggesting a role for neuronal plasticity and neuroprotection.

  • Brexpiprazole has been approved by the US Federal Drug Administration based on four completed Phase III trials, two each for schizophrenia and the adjunctive treatment of major depressive disorder. Phase III trials for agitation in Alzheimer’s disease and for adjunctive use in post-traumatic stress disorder are ongoing.

Notes

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.